10:16 AM EDT, 06/20/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday that topline results from an interim analysis of a phase 3 trial of lenacapavir for HIV prevention in cisgender women demonstrated 100% efficacy.

The trial met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada and background HIV incidence, the company said.

Gilead said that based on the trial results the independent Data Monitoring Committee recommended stopping the blinded phase of the trial and offer open-label lenacapavir to all participants.

Shares of Gilead Sciences ( GILD ) were up 4% in recent trading.

Price: 65.85, Change: +2.70, Percent Change: +4.28